Are You Managing Vendor Risk—or Just Documenting It?

Your oversight plan is approved. Your KPIs are tracked. Your eTMF holds the records. But can you demonstrate what happened between identifying a vendor risk and resolving it?

Clinical trial sponsors invest considerable effort in CRO oversight plans, governance meetings, quality systems and inspection documentation. Yet when evidence is needed, teams may still have to piece together decisions, responsibilities and follow-through across disconnected records. What is missing?

Download the Article (PDF)

What Happens Between a Performance Signal and a Resolved Issue?

A missed CRO performance threshold appears on a dashboard. It is discussed in a governance meeting, and an action is assigned. Two months later, the same issue returns. Can the team quickly show what was decided, who was accountable, whether the action was completed and how the risk was reassessed?

The answer reveals a distinction that matters: documenting oversight is not the same as demonstrating that oversight worked.

WHAT READERS WILL EXPLORE

• Why an approved oversight plan is a starting point—not evidence of execution.
• The governance activities that can fall between a QMS and an eTMF.
• What ICH E6(R3) means for risk-proportionate sponsor oversight and follow-through.
• Why “inspection steadiness” may be a more useful operating ambition than last-minute inspection readiness.
• Where AI can help connect governance information—and why traceability and human judgment still matter.
• Explore VISION Plus — AI-Native Pharma Vendor Oversight & Governance

Could Your Team Demonstrate Continuous Oversight Today?

Explore the questions, practical examples and governance perspective behind a different approach to CRO oversight.

Download the Article (PDF)

AUTHOR ATTRIBUTION

Anca Copaescu is the Founder and CEO of Clinical Maestro and has held leadership roles in clinical outsourcing, vendor management and corporate development across pharmaceutical, biotechnology and CRO organizations.